AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
Phase 4
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2016-11-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT02153489
- Locations
- 🇩🇪
Pulmonary Research Institute at the Lung Clinic Grosshansdorf, Grosshansdorf, Germany
🇩🇪Pneumologische Lehrklinik der Universitätsmedizin Göttingen, Immenhausen, Germany
Multicentric, Transversal, Descriptive, Epidemiological Study on the Management of Asthma in Asthmatic Middle East Adult Population
Completed
- Conditions
- Asthma
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 7294
- Registration Number
- NCT02153411
- Locations
- 🇦🇪
Research Site, Sharjah, Nis-rme-xxx-2014/1, United Arab Emirates
A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases
Phase 3
Completed
- Conditions
- Reflux Esophagitis (RE)Zollinger-Ellison SyndromeDuodenal Ulcer (DU)Non-erosive Reflux Esophagitis Disease (NERD)Gastric Ulcer (GU)Anastomotic Ulcer (AU)
- Interventions
- Drug: D961H sachet 10 mgDrug: D961H capsule 20 mgDrug: D961H capsule 10mg
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 55
- Registration Number
- NCT02153398
- Locations
- 🇯🇵
Research Site, Yokohama-shi, Japan
AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3
Completed
- Conditions
- Anticancer Treatment
- Interventions
- Drug: ChemotherapyDrug: Cross-over to Osimertinib
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 421
- Registration Number
- NCT02151981
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: budesonide/formoterol 'as needed' + budesonide placebo bid
- First Posted Date
- 2014-05-29
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3850
- Registration Number
- NCT02149199
- Locations
- 🇻🇳
Research Site, Hochiminh, Vietnam
AZD9291 in Combination With Ascending Doses of Novel Therapeutics
Phase 1
Active, not recruiting
- Conditions
- Advanced Non Small Cell Lung Cancer
- Interventions
- Drug: Part A - AZD9291 in combination with AZD6094Drug: Part A - AZD9291 in combination with continuous selumetinib (Asian subjects)Drug: Part A - AZD9291 in combination with MEDI4736Drug: Part C - AZD6094 monotherapy (Japan only)Drug: Part B - AZD9291 in combination with AZD6094Drug: Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)Drug: Part B - AZD9291 in combination with MEDI4736Drug: Part C - AZD9291 in combination with AZD6094 (Japan only)Drug: Part A - AZD9291 in combination with intermittent selumetinibDrug: Part D - AZD9291 in combination with AZD6094Drug: Part B - AZD9291 in combination with selumetinib
- First Posted Date
- 2014-05-21
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 344
- Registration Number
- NCT02143466
- Locations
- 🇺🇦
Research Site, Vinnytsia, Ukraine
Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor
- Interventions
- First Posted Date
- 2014-05-21
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT02144051
- Locations
- 🇬🇧
Research Site, London, United Kingdom
The Severity of Newly Diagnosed Asthma Patients and the Result of Initial 12 Weeks Treatment in China
Completed
- Conditions
- Asthma
- First Posted Date
- 2014-05-21
- Last Posted Date
- 2017-09-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4817
- Registration Number
- NCT02143739
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma
Phase 1
Completed
- Conditions
- Part A and B: Advanced Solid MalignanciesPart C: Malignant Mesothelioma
- Interventions
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2018-12-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 65
- Registration Number
- NCT02141347
- Locations
- 🇯🇵
Research Site, Yokohama-shi, Japan
Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
Phase 3
Completed
- Conditions
- Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1656
- Registration Number
- NCT02138916
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom